SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Fresenius Kabi Oncology to ink agreement with Fresenius Kabi Germany and its affiliates

27 May 2011 Evaluate

Fresenius Kabi Oncology has received board’s approval for entering into contract R&D and manufacturing agreements with Fresenius Kabi Germany and its affiliates for future products without affecting existing product business and Intellectual Property Rights (IPRs).

The company received the approval at its board meeting held on May 26, 2011. The company has decided to enter into an agreement with the view to further leverage its R&D and manufacturing competencies. The company has also received an approval for entering into a distribution agreement with Fresenius Kabi India for selling and marketing its products in India.

Further, Fresenius Kabi Oncology has also received an approval for disinvestment of its entire shareholding in Fresenius Kabi Oncology Plc, UK - a wholly owned subsidiary of the company to Fresenius Kabi Germany and its affiliates. The agreements will come into effect after obtaining all necessary internal approvals and signing of the same, which can be expected in June 2011.

Fresenius Kabi Oncology is a leading Indian company for cancer research and anticancer products. The company uses the services of Dabur Research Foundation (DRF) for research and development activities. The pharma major market its products in various parts of the world namely Bangladesh, Sri Lanka, Thailand, Philippines, Malaysia, Vietnam, Myanmar, Jordan, Russia, Ukraine, Georgia, Kazakhstan, Uzbekistan, Hungary, Kenya, Nigeria, Ghana, Zimbabwe, Brazil, Venezuela and Mexico, among others.

Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×